Administration of DAA-based treatment — Competitive Intelligence Brief

Administration of DAA-based treatment (Administration of DAA-based treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination. Area: Virology / Hepatology.

phase 3 Direct-acting antiviral (DAA) combination HCV NS3/4A protease, HCV NS5B polymerase, HCV NS5A protein (depending on specific DAA regimen) Virology / Hepatology Small molecule

Target snapshot

Administration of DAA-based treatment (Administration of DAA-based treatment) — Ain Shams University. DAA-based treatment directly inhibits hepatitis C virus (HCV) nonstructural proteins to block viral replication and cure chronic HCV infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of DAA-based treatment TARGET	Administration of DAA-based treatment	Ain Shams University	phase 3	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, HCV NS5B polymerase, HCV NS5A protein (depending on specific DAA regimen)
sofosbubir/velpatasvir/voxilaprevir	sofosbubir/velpatasvir/voxilaprevir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase, NS5A protein, NS3/4A protease
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
Sofosbuvir/Velpatasvir + Ribavirin	Sofosbuvir/Velpatasvir + Ribavirin	Peking University People's Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase, HCV NS5A protein
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
EXVIERA	EXVIERA	HaEmek Medical Center, Israel	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS5B, NS3/4A protease
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination class)

1. Massachusetts General Hospital · 3 drugs in this class
2. Egyptian Liver Hospital · 3 drugs in this class
3. Hannover Medical School · 2 drugs in this class
4. University of Maryland, Baltimore · 2 drugs in this class
5. Iran Hepatitis Network · 2 drugs in this class
6. Partners in Health · 2 drugs in this class
7. HaEmek Medical Center, Israel · 1 drug in this class
8. Almaza Military Fever Hospital · 1 drug in this class
9. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
10. Federal University of São Paulo · 1 drug in this class